### **REMARKS/ARGUMENTS**

## **Introductory Remarks**

Claims 1, 3-16, 19-26, 29-32, 38-45, 47-52, 54, 56, 58-60, 62-68, 70, 72, and 74-85 are pending in the application. Claims 1, 10, 13, 14, 26, 38, 39, 48, 51, and 56 have been amended. The amendments do not include new matter. Claims 2, 4, 11, 16-18, 27-28, 33-37, 41, 46, 53, 55, 57, 61, 69, 71, and 73 have been canceled. New claims 74-85 have been added herein. New claims 74-85 do not involve new matter. Support for new claims 74-85 can be found throughout the specification, e.g. in Example 6, at p. 43-47 of the 60/439,376 ('376 application), filed 01/10/2003.

## Interview Summary

Applicants' attorney Stankovic conducted a telephonic interview with Examiner Medina on April 27, 2009, in order to address outstanding rejections in the present application. In particular, claim amendments to overcome the rejections were discussed. The Examiner is thanked for her consideration in this matter.

### **Priority**

The Office Action contends that the disclosure of the prior-filed provisional patent application, No. 60/439,376 ('376 application), filed 01/10/2003, fails to provide adequate support or enablement in the manner provided by the first paragraph of 35 U.S.C. § 112 for one or more claims of the application. In particular, the Office Action contends that the nucleic acid sequences of SEQ ID NOs:4 and 7 and the polypeptide sequences of SEQ ID NOs:5 and 8 are not disclosed in the provisional application. The Office Action therefore contends that "the effective filing date of claims drawn to SEQ ID NO:4, 7, and nucleic acids encoding SEQ ID NO:5 and 8 is 01/12/2004." Applicants respectfully disagree.

# 1. Disclosure of BAC clone 177O13 in the '376 parent application

First, as indicated in the '376 provisional (parent) patent application, the inventors identified, **disclosed BAC clone 177O13**, and used it for the isolation of the late blight resistance gene of the present invention (e.g., page 39 and SEQ ID NO:1 of the '376 parent application). Therefore, the inventors' disclosure of the BAC clone 177O13 in the '376 parent application, filed 01/10/2003, was before the effective filing date of the Jacobus *et al.* patent application, U.S. 20030221215A1, filed 02/07/2003. It is noted that the Office Action refers to the 20030221215A1 patent application as Allefs *et al.* 

Second, the Office Action indicates that "the BAC clone was publicly available as of 05/23/03 which is after the affective filing of Allefs et al." That is not relevant, as the inventors disclosed BAC clone 177O13 in the '376 parent application that was filed on 01/10/2003, which is prior to the effective filing date of the Jacobus *et al.* patent application, U.S. 20030221215A1, and prior to the public disclosure of the BAC clone.

## 2. <u>Disclosure of SEQ ID NO:4 in the '376 parent application</u>

First, shown in SEQ ID NO:4, at p. 69-71 of the '376 parent application, is a "nucleic acid sequence of disease resistant gene, gene 2 (cloned by PCR). Two exons are highlighted in bold. A single intron is underlined." ('376 application, p. 69; see also Appendix I). When these two identified exons, shown in bold, are joined together, the resulting nucleic acid sequence is 100% identical to the nucleic acid sequence of SEQ ID NO:4 of the instant application. The '376 parent application thus identifies and points out the "two exons" (shown in bold) that need to be joined together and the "single intron" (underlined) that needs to be removed in order to obtain a coding region.

Because the specification refers to two exons and a single intron, and graphically describes them (bold and underlined, respectively), one skilled in the art would know to join the two exons together while removing the single intron, in order to obtain the coding region of SEQ ID NO:4. Therefore, the nucleic acid sequence

Application Serial No. 10/755,966 Response dated July 30, 2009 Reply to Office Action of April 30, 2009

of SEQ ID NO:4 of the instant application was fully disclosed in the '376 application.

Second, the entire nucleic acid sequence of SEQ ID NO:4 of the instant application is also shown in the '376 parent application in Example 6, at p. 43-47 of the '376 application (see also Appendix II), in a nucleic acid comparison (alignment). As indicated at p. 43, I. 57-58 of the '376 parent application, the top sequence in the comparison presented in Example 6 refers to the "gene 2 coding region from the resistant homolog". This nucleic acid sequence, disclosed in the '376 parent application, is 100% identical to the nucleic acid sequence of SEQ ID NO:4 of the instant application. In order to advance prosecution of the present application, Applicants request that the Examiner point out the alleged differences in the sequences.

## 3. Disclosure of SEQ ID NO:5 in the '376 parent application

Shown as SEQ ID NO:5, at p. 71 of the '376 parent application (see also Appendix III), is a "Gene 2 protein sequence (from the resistant homolog)". This amino acid sequence, disclosed in the '376 parent application, is **100% identical to the amino acid sequence of SEQ ID NO:5** of the instant application. Therefore, the amino acid sequence of SEQ ID NO:5 of the instant application was fully disclosed in the '376 parent application. In order to advance prosecution of the present application, Applicants request that the Examiner point out the alleged differences in the sequences.

Accordingly, Applicants respectfully request that the instant application is accorded the correct priority date that corresponds to the date of the filing of the '376 parent provisional patent application, i.e., **January 10, 2003**. Amended claims 1, 10, 13, 14, 26, 38, 39, 48, 51, and 56, and claims dependent from these amended claims, should be accorded the correct priority date that corresponds to the date of the filing of the '376 parent provisional patent application, i.e., **January 10, 2003**.

Application Serial No. 10/755,966 Response dated July 30, 2009 Reply to Office Action of April 30, 2009

## Claim Rejections - 35 U.S.C. §102

Claims 1,3-16, 19-22, 24-26, 29-32, 38-41, 43-45, and 66 are rejected under 35 U.S.C. 102(e) as allegedly being anticipated by Jacobus *et al.*, U.S. 20030221215A1, published 11/27/2003 (<u>Jacobus</u>). It is noted that the Office Action refers to the 20030221215A1 patent application as Allefs *et al.* <u>Jacobus</u> is published after the priority date of the present patent application (i.e., after 1/10/2003). Therefore, <u>Jacobus</u> does not qualify as a 35 U.S.C. 102(e) reference. Applicants respectfully request that this rejection be withdrawn.

## Claim Rejections - 35 U.S.C. §103

It is not clear from the Office Action which claims have been rejected under 35 U.S.C. 103(a), as allegedly being obvious over Jacobus *et al.*, U.S. 20030221215A1, published 11/27/2003 (<u>Jacobus</u>) in view of Staskawics et al., US 6,166,295 (<u>Staskawics</u>). However, because <u>Jacobus</u> is published after the priority date of the present patent application (i.e., after 1/10/2003), <u>Jacobus</u> does not qualify as a 35 U.S.C. 103(a) reference. Applicants respectfully request that this rejection be withdrawn.

### SUMMARY

The claims at issue distinguish over the cited references and are in condition for allowance. Applicants respectfully request the Examiner grant early allowance of this application. The Examiner is invited to contact the undersigned attorney for Applicants via telephone at (312) 321-4254 if such communication would expedite this application.

Application Serial No. 10/755,966 Response dated July 30, 2009 Reply to Office Action of April 30, 2009

Respectfully submitted,

/Bratislav Stankovic, Reg. No. 56,999/ Bratislav Stankovic, Ph.D. Registration No. 56,999 Attorney for Applicants

BRINKS HOFER GILSON & LIONE P.O. BOX 10395 CHICAGO, ILLINOIS 60610 (312) 321-4200

## Appendix I

EDGLID, 875FEHD6

#### P03170US/WARF-0204

NLRALTSLDISDNVEATSLPEEMFKSLANLKYLKISFFRNLKELPTSLASLNALKSLKFEFCDALESLPE EGVKGLTSLTELSVSNCMMLKCLPEGLQHLTALTTLTITQCPIVFKRCERGIGEDWHKIAHIPYLTLYE

SEQ ID NO:4: Nucleic acid sequence of disease resistant gene, gene 2 (cloned by PCR). Two exons are highlighted in bold. A single intron is underlined.

CGGGATCCTCTCACATAAATTGACACAAAGGGAGTACTTGTTAATGTTGTAATTATTGGCGAACAATAAT GTTGTTGATTATCACTTTCTGAATAAGTGTTGTGTCACTTGGAAAAAAACACCAAATAGAACTATTCATGT TTTTTCTTTAGTATATATAAATATGATCTTTAACTTAATTTCAGCAGACAGTCATGATCTTTAACTTTAA ATGTGCACAAGTAGATTGACAGGCTTGCTAATTGAGTGTCTGTTATAATCAGTATTAAATACTCTCAAGG TANTAGTATATTCCAGACAAATTTTGTGTTACCAAATTAAATATATTTCTAAAACTCTCCTCAAAGTAGT TAATATACTTTTGAGTGTTGTATCATGTTTTTAATATAAAATGTTAAAATTTAGATGAAATTTACTTTCT AGTTAAATTGGTCAAAGTTGAAAGAATTTCAAGTGAAAAAGTTTTTAATAATTTGACTTTTATGCTATAT GCCCTTTATATGATGAAAAAAAAAAAAAGAAATTAGATGACAACAATGTCCAAAAAATAATCTTAAAGAAT GATAAATTTTTTTTTTTTTTTTTTTTACTAATTGCGTATAGAGAAAAGGAAAATGGGGCGGTAATTAC AACAGTACTTCATCTATTCTATTAATTAAATTTTCTATATTAATTAAATTTGTGAGGTAATACAAACT TATTAAGAAAAATATTTAAGGACATAATTTAACTCATATTTTTCACTATTGTTTTTTTGTGAAATCATAAA TATAACTTTGTAAATAGTGCAATTTATCTCCTAGAAGCAAATTTCACCAAAGAAAAGGGCAAAGATGGAA AAGAAACTAAATATTCATCTTAAACTTTGAACAATTCAATTATTTTGAACAATGAAAAAATCTCAAAAA TTCAATTAATATGAAATGGAGAGAGTAACTTTATTTTAGAGGCAAAAAATTAGTACTCCATCCGTTCACT TTTATTTGTCATGTTGCGCTTTTCGAAAGTCAATTTGACTAATTTTTAAAGCTAAATTAGATTACACTAA TTCAATATTTTAAACAGAAAAATTAGATATTCAAAAACTATACAAAAAATATTATACATTGCAATTTTTT GCATATCAATATGATAAAAAAATATTGTAAAATATTAGTCAAAATTTTTATAGTTTGACTCTAATCAT GAAAAGTATAATAATTAATAGTGGACGGAGGAAGTATTGTCTTTCCAGATTTGTGGCCATTTTTGGGCCA AGGGCCATTAGCAGTTCTCTTCATTTTCTACTTCTGTCTCATATTAGATGGGCATCTTACTAAAAATATT ATTAATATAGTTTTAAAAGTTTTAAACAAATTTTGAAGAATCAAAATTTCTTTTTGCAAGAGACTTATTA ATATAAACAAAGGATAAAATAAAAATTTGTCAATTTATTGACGATCACTTAATAATCATATAAAAATAG antatgtttatctaatatgagacggagaaaatatatcctaaaatatttttggacagatatgtgatattct TTCGATTTTTATTTTATTTATCACTTTTAACCTATCATGTAAAAAGATAATTATTTTTTCATGCTTTA AATTTGTCCGGTCAAACAATGATAAATAAAAACGAATGAAGAGAGTAGAAAACAAAACAAAAGAACAAGT TGACAACTTGAGAGATTAAAAGGGTCCAAAACGCCTTGGATTTTGAGATTCCATATGTGAAAATTTCCATG AAATAATTGAATTTGTATTACTACAAGTCAAACTTCCCATTTCATTCCAACTAGCCATCTTGGTTTCAAA ATTACACATTCATTCACAGATCTAATATTCTTAATAGTGATTTCCACATATGGCTGAAGCTTTCAT tcaagttctgctagacaatctcacttcttcctcaaaggggaacttgtattgcttttcggtttcaagat Gagttccaaaggctttcaagcatgttttctacaattcaagccgtccttgaagatgctcaggagaagcaac TCAACAACAAGCCTCTAGAAAATTGGTTGCAAAAACTCAATGCTGCTACATATGAAGTCGATGACATCTT 45 GGATGAATATAAAACCAAGGCCACAAGATTCTCCCAGTCTGAATATGGCCGTTATCATCCAAAGGTTATC CCTTTCCGTCACAAGGTCGGGAAAAGGATGGACCAAGTGATGAAAAAACTAAAGGCAATTGCTGAGGAAA GAAAGAATTTTCATTTGCACGAAAAAATTGTAGAGAGACAAGCTGTTAGACGGGAAACAGGTACTCATCT CTGTCTAACTCATCCACTACCCATTCCCTTTGCTTTGAATTCTTTTCTTTACCTATAAACGTGGAACACT CGATCCGTTTTGCTTTCTTAACAAAGCAGCTCAGAGAAAAGAGGTTTTCTTCTATTCTGTTTCTCTGTG

TGCTGCACTTGGGTCCTTAATCCCATTAAAAACAGGGCATGTTAATCCCAACGACGGTAGCCTTTCCTGA
CAGCTGACTGTAAATTTTGTCTAACAAAGAAAAAAAAAGATTAGACATGTTTTTCCTTGTCATTGATTAG
GCTGGATTTCTTTCAGAGTGGAACATAGGGGATATATTGGACCAAAAGTAGAATGGGTATATATTTAAAG

SDD110.3752003

#### P03170US/WARF-0204

TATTTCTGATAGAACAGGAGTATATTGTGCGAAAATATCCTCTATTTTCTGTTGTCTCCTAATGAGTT AAGAGACAAGAGAAAGATGAGATAGTGAAAAATCCTAATAAACAATGTTAGTGATGCCCAACACCTTTCA GTCCTCCCAATACTTGGTATGGGGGGATTAGGAAAAACGACTCTTGCCCAAATGGTCTTCAATGACCAGA GAGTTACTGAGCATTTCCATTCCAAAATATGGATTTGTGTCTCGGAAGATTTTGATGAGAAGAGGTTAAT aaagccaattgtagaatctattgaaggaaggccactacttggtgagatggacttggctccacttcaaaag **AAGCTTCAGGAGTTGCTGAATGGAAAAAGATACTTGCTTTGTCTTAGATGATGTTTTGGAATGAAGATCAAC** AGAAGTGGGCTAATTTAAGAGCAGTCTTGAAGGTTGGAGCAAGTGGTGCTTCTGTTCTAACCACTACTCG tcttgaaaaggttggatcaattatgggaacattgcaaccatatgaactgtcaaacctgtctcaagaagat 10 Gaaaggagattgtgaaaaaagtggtggtgtgcctctagcagccaaaactcttggaggtattttgtgctt CAAGAGAGAAGAAGAGCATGGGAACATGTGAGAGACAGTCCGATTTGGAATTTGCCTCAAGATGAAAGT TCTATTCTGCCTGCCCTGAGGCTTAGTTACCATCAACTTCCACTTGATTTGAAACAATGCTTTGCGTATT TCTTTATCAAAAGGAAACATGGAGCTAGAGGATGTGGGCGATGAAGTATGGAAAGAATTATACTTGAGG TCTTTTTCCAAGAGATTGAAGTTAAAGATGGTAAAACTTATTTCAAGATGCATGATCTCATCCATGATT **ACATATGATGTCCATTGGTTTCGCCGAAGTGGTGTTTTTTTACACTCTTCCCCCCTTGGAAAAGTTTATC** TCGTTAAGAGTGCTTAATCTAGGTGATTCGACATTTAATAAGTTACCATCTTCCATTGGAGATCTAGTAC ATTTAAGATACTTGAACCTGTATGGCAGTGGCATGCGTAGTCTTCCAAAGCAGTTATGCAAGCTTCAAAA tctgcaaactcttgatctacaatattgcaccaagctttgttgtttgccaaaagaaaccaagtaaacttggt **AGTCTCCGAAATCTTTTACTTGATGGTAGCCAGTCATTGACTTGTATGCCACCAAGGATAGGATCATTGA** CATGCCTTAAGACTCTAGGTCAATTTGTTGTTGGTAGGAAGAAAGGTTATCAACTTGGTGAACTAGGAAA cctaaatctctatggctcaattaaaatctcgcatcttgagagagtgaagaatgatatggacgccaaaagaa GCCAATTTATCTGCAAAAGGGAATCTGCATTCTTTAAGCATGAGTTGGAACATAACTTTGGACCACATATAT ATGAATCAGAAGAAGTTAAAGTGCTTGAAGCCCTCAAACCACACTCCAATCTGACTTCTTTAAAAATCTA TGGCTTCAGAGGAATCCATCTCCCAGAGTGGATGAATCACTCAGTATTGAAAAATATTGTCTCTATTCTA ATTAGCAACTTCAGAAACTGCTCATGCTTACCACCCTTTGGTGATCTGCCTTGTCTAGAAAGTCTAGAGT TACACTGGGGGTCTGCGGATGTGGAGTATGTTGAAGAAGTGGATATTGATGTTCATTCTGGATTCCCCAC AAGAATAAGGTTTCCATCCTTGAGGAAACTTGATATATGGGACTTTGGTAGTCTGAAAGGATTGCTGAAA AAGGAAGGAGAAGAGCAATTCCCTGTGCTTGAAGAGATGATAATTCACGAGTGCCCTTTTCTGACCCTTT CTTCTAATCTTAGGGCTCTTACTTCCCTCAGAATTTGCTATAATAAAGTAGCTACTTCATTCCCAGAAGA GATGTTCAAAAACCTTGCAAATCTCAAATACTTGACAATCTCTCGGTGCAATAATCTCAAAGAGCTGCCT accagettggetagtetgaatgetttgaaaagtetaaaaattgagtgtgeggaetagagagtetc CTGAGGAAGGCTGGAAGGTTTATCTTCACTCACAGAGTTATTTGTTGAACACTGTAACATGCTAAAATG 35 TTTACCAGAGGGATTGCAGCACCTAACAACCCTCACAAGTTTAAAAATTCGGGGATGTCCACAACTGATC **TTTAA**GTTATTTGCTATTGTTTGTTTGTGAGTCTTTTTGGTTCCTGCCATTGTGATTGCATGTAAT  $\tt TTTTTTCTAGGGTTGTTTGTTTGAGTCTCTCTCTCTCATTGGATGTAATTCTCTTTTGGTAACAAATTA$ TGAGTATCTTATTGTATGGAATTTTCTGATTTTATTTTGAAAACAAATCAATAAGATCCATCTGCATTAT ACTCCCTTCGTCTCATTTTATGTGACACTTTTTGGATTTCGAGATTCTTTGATCTTAAATTTTTCATAGA TCTTTTAAACATTTTGAGTTATCAATTATTGTGATTTTAGTATTTTTTATGTAGTTTACAAATACATAAA ATTTATTTTTTTAAAAAAAGAAGATTTCATGCGCAAATTCCCGATCAAACTTAAATTACTAGACTCTCG 45  ${\tt AAAAATGAAAAGTGTCACATAAATTGAGACAGAGGGAGTACTTGTTAATGTTGTAATTATTGGCGAACAA}$ TAATGTTGGTGATTATCACTTTCTGAATAAATGTTGTGTCACGTGGAAAAAACACCAAATAGAAGTATTC ATGCTTTTTTAGTATATATAAACATGATTTTTAACTTGGTTTCAGCGGATAGTCATGACCTTTAACTCTG **AATGTGCACAAGTAGATACTTGTATAAAATTAAAACAAATTTTATAAAATTATACAATATGACACTGAGAG** TAATTGATACCAATTGCAGTCGTTGCTGCTTTTCGATTCTCTGTCATTCTCTAGGTAATTGATTTTACAG AAAATATCCTTCTACTCATCCTTTTTTGTCTAAAATTACCCTTTCATCCACATTTTTTGCTCACTTATACC AGATAATTAAAATATCTTTAAAAGTACTAGTCATGCCACAATTATAGGGACATAATATATTAATATAAAT 

# Appendix II

## P03170US/WARF-0204

60439376.011003

	351	PLAAKTLGGILCFKREERAWEHVRDSPIWNLPQDESSILPALRLSYHQLP	400
5	351	PI.AAKTLGGILCFKREERAWEHVRDSPIWNLPQDESSILPALRLSYHQLP	400
	101	LDLKQCFAYCAVFPKDAKMEKFKLISIMMAHGFLLSKGNMELEDVGDEV.	450
	401	LDLKQCFAYCAVFPKDAKMKKEKLISIWMAHGFLLSKGNMELEDVGDEVW	450
10	451	KEL+LRSFFQEIEVKDGKTYFKMHDLJHDLATSLFSANTSSSNIREINKH	500
•	451	KELYLRSFFQEIEVKDGKTYFKMHDL1HDLATSLFSANTSSSNIREINKH	500
15	501	SYTHMMSIGFAEVVFFYTLPPLEKFISLRVLNLGDSTFNKLPSSIGDLVH	550
	501	SYTHMMSIGFAEVVFFYTLPPLEKFISLRVLNLGDSTFNKLPSSIGDLVH	550
	551	LRYLNLYGSGMRSLPKQLCKLQNLQTLDLQYCTKLCCLPKETSKLGSLRN	600
20	551	LRYLNLYGSGMRSLPKQI.CKI.QNI.QTLDI.QYCTKLCCLPKETSKI.GSLRN	600
	601	LLLDGSQSLTCMPPRIGSLTCLKTLGQFVVGRKKGYQLGELGNLNLYGSI	650
25	601	LLLDGSQSLTCMPPRIGSLTCLKTLGQFVVGRKKGYQLGELGNLNLYGSI	650
	651	KISHLERVKNDKUAKEANLSAKGNLHSLSMSWNNFGPHIYESEEVKVLEA	700
		KISHLERVKNDMDAKEANLSAKGNLHSLSMSWNNFCPHIYESEEVKVLEA	
30	701	LKPHSNLTSLKIYGFRGIHLPEWMNHSVLKNIVSILISNFRNCSCLPPFG	750
	701	LKPHSNLTSLKTYGFRGIHLPFWMNHSVLKNJVS1LISNFRNCSCLPPFG	750
35		DLPCLESLELHWGSADVEYVEEVDIDVHSGFPTRIRFPSLRKLDIWDFGS	• • •
		DLPCLESLEIJIWGSADVEYVEEVDIDVHSGFPTRIRFPSLRKLDIWDFGS	
40		LKGLLKKEGEEQFPVLEEMITHECPFLTLSSNLRALTSLRICYNKVATSF	
40		LKGLLKKEGEEQFPVLEEMIIHECPFLTLSSNLRALTSLRICYNKVATSF	
		PEEMFKNLANLKYLTISRCNNLKELPTSLASLNALKSLALESLP	
45		PEEMFKNLANLKYLTISRCNNLKELPTSLASLNALKSLKIQLCCALESLP	
		EEGLEGLSSLTELFVEHCNMLKCI,PEGLQHLTTLTSLKIRGCPQLIKRCE	
50		EEGLEGLSSLTELFVEHCNMLKCLPEGIQHLTTLTSLKIRGCPQLIKRCE KGJGEDWHKISHIPNVNIY1* 965	950
		KGIGEDMHKISHIPNVNIYI' 971	
	,,,,	WOTOPOWERFULLANTIII. ALT	

## 55 Example 6:

The following example shows a nucleic acid comparison between the gene 2 coding regions from a disease resistant and disease susceptible variety. The top sequence is the gene 2 coding region from the resistant homolog. The bottom sequence is the gene 2 coding region

#### P03170US/WARF-0204

## SOCILO, ASSERVA

from the susceptible 177013 homolog. Note that the susceptible homolog contains a C to G point mutation at position 1362 that creates a stop codon in second exon at Tyr454 (residue 454 of 970 total), creating a severely truncated protein, in addition to one mismatch (C to T) at codon 10 which doesn't change the amino acid and one sense mutation (T to C) at codon 22 which alters value to alanine.

## P03170US/WARF-0204

# SOUISSEA GOLLOGS

	651	TGATGAGAAGAGGTTAATAAAGGCAATTGTAGAATCTATTGAAGGAAG	700
		TGATGAGAAGAGGTTAATAAAGGCAATTGTACAATCTATTGAAGGAAG	
5	701	CACTACTTGGTGAGATGGACTTGGCTCCACTTCAAAAGAAGCTTCAGGAG	750
	2195		2146
10	751	TTGCTGAATGGAAAAAGATACTTGCTTGTCTTAGATGATGTTTTGGAATGA	800
	2145	[;;	2096
	801	AGATCAACAGAAGTGGGCTAATTTAAGAGCAGTCTTGAAGGTTGGAGCAA	850
15	2095	AGATCAACAGAAGTCGGCTAATTTAAGAGCAGTCTTGAAGGTTCGAGCAA	2046
	851	GTGGTGCTTCTGTTCTAACCACTACTCGTCTTGAAAAGGTTGGATCAATT	900
20	2045	GTGGTGCTTCTGTTCTAACCACTACTCGTCTTGAAAAGGTTGGATCAATT	1996
20	901	ATGGGAACATTGCAACCATATGAACTGTCAAACCTGTCTCAAGAAGATTG	950
	1995	ATGGGAACATTGCAACCATATGAACTGTCAAATCTGTCTCAAGAAGATTG	1946
25	951	TTGGTTGTTCATCCAACGTGCATTTGGACACCAAGAAGAAATAAAT	1000
	1945	TTGGTTGTTCATGCAACGTGCATTTGGACACCAAGAAGAAATAAAT	1896
30	1001	CAAACCTTGTGGCAATCGGAAAGGAGATTGTGAAAAAAAGTGGTGGTGTG	1050
	1895	CAAACCTTGTGGCAATCGGAAAGGAGATTGTGAAAAAAAGTGGTGGTGTG	1846
	1051	CCTCTAGCAGCCAAAACTCTTGGACGTATTTTGTCCTTCAAGAGAGAAGA	1100
35	1845	CCTCTAGCAGCCAAAACTCTTGGAGGTATTTTGTGCTTCAAGAGAGAAGA	1796
	1101	AAGAGCATGGGAACATGTGAGAGACAGTCCGATTTGGAATTTGCCTCAAG	1150
40		AAGAGCATGCGAACATGTGAGAGACAGTCCGATTTGGAATTTGCCTCAAG	
		ATGAAAGTTCTATTCTGCCTGCCCTGAGGCTTAGTTACCATCAACTTCCA	
4.5		ATGAAAGTTCTATTCTGCCTGCCCTGAGGCTTAGTTACCATCAACTTCCA	
45	•	CTTGATTTGAAACAATGCTTTGCGTATTGTGCGGTGTTCCCAAAGGATGC	
		CTTGATTTGAAACAATGCTTTGCGTATTGTGCGGTGTTCCCAAAGGATGC	
50		CAAAATGAAAAAAGCTAATCTCTCTCTGGATGGCGCATGGTTTTC	
		CAAAATGGAAAAACAAAAGCTAATCTCTCTCTGGATGGCCCATGGTTTTC	
55		TTTTATCAAAAGGAAACATGGAGCTAGAGGATGTGGGCGATGAAGTATGG	
		TTTTATCANAAGGAAACATGGAGCTAGAGGATGTGGGCGATGAAGTATGG AAAGAATTATACTTGAGGTCTTTTTTCCAAGAGATTGAAGTTAAAGATGG	
60		AAAGAATTATACTTGAGGTCTTTTTCCAAGAGTTGAACTTAAAGATGG	
		TAAAACTTATTCAAGATGCATGATCTCATCATGATTTGGCAACATCTC	
		HILLIH HILLIH HILLIH HILLIH HILLIH HILLIH HILLIH	1450

### SOTISTS PLACES P03170US/WARF-0204 1495 TAAAACTTATTTCAAGATGCATGATCTCATCCATGATTTGGCAACATCTC 1416 5 1501 AGTTACACACATATGATGTCCATTGGTTTCGCCGAAGTGGTGTTTTTTTA 1550 10 1551 CACTCTTCCCCCCTTGGAAAAGTTTATCTCGTTAAGAGTGCTTAATCTAG 1600 15 1601 GTGATTCGACATTTAATAAGTTACCATCTTCCATTGGAGATCTAGTACAT 1650 1295 GTGATTCGACATTTAATAAGTTACCATCTTCCATTGGAGATCTAGTACAT 1246 1651 TTAAGATACTTGAACCTGTATGGCAGTGGCATGCGTAGTCTTCCAAAGCA 1700 20 1701 GTTATGCAAGCTTCAAAATCTGCAAACTCTTGATCTACAATATTGCACCA 1750 25 1751 AGCTTTGTTTGCCAAAAGAAACAAGTAAACTTGGTAGTCTCCGAAAT 1800 AGCTTTGTTTGCCAAAAGAAACAAGTAAACTTGGTAGTCTCCGAAAT 1096 30 1801 CTTTTACTTGATGGTAGCCAGTCATTGACTTGTATGCCACCAAGGATAGG 1850 35 1901 AAGGTTATCAACTTGGTGAACTAGGAAACCTAAATCTCTATGGCTCAATT 1950 40 45 2001 CAATTTATCTGCAAAAGGGAATCTGCATTCTTTAAGCATGAGTTGGAATA 2050 50 2051 ACTTTGGACCACATATATATGAATCAGAAGAACTTAAAGTGCTTGAAGCC 2100 55 2151 AATCCATCTCCCAGAGTGGATGAATCACTCAGTATTGAAAAATATTGTCT 2200 60 745 AATCCATCTCCCAGAGTGGATGAATCACTCAGTATTGAAAAATATTGTCT 696

### P03170US/WARF-0204

# SOTIOS STEPSTO

	2201	CTATTCTAATTAGCAACTTCAGAAACTGCTCATGCTTACCACCCTTTGGT	2250
	695	CTATTCTAATTAGCAACTTCAGAAACTGCTCATGCTTACCACCCTTTGGT	646
5	2251	GATCTGCCTTGTCTAGAAAGTCTAGAGTTACACTGGGGGTCTGCGGATGT	2300
	. 645	GATCTGCCTTGTCTAGAAAGTCTAGAGTTACACTGGGGGTCTGCGGATGT	596
10	2301	GGGGTATGTTGAAGAAGTGGATATTGATGTTCATTCTGGATTCCCCACAA	2350
	595	GGAGTATGTTGAAGAAGTGGATATTGATGTTCATTCTGGATTCCCCACAA	546
	2351	GAATAAGGTTTCCATCCTTGAGGAAACTTGATATATGGGACTTTGGTAGT	2400
15	545	GAATAAGGTTTCCATCCTTGAGGAAACTTGATATATGGGACTTTGGTAGT	496 .
	2401	CTGAAAGGATTGCTGAAAAACGAAGGAGAAGAGCAATTCCCTGTGCTTGA	2450
20	495	CTGAAAGGATTGCTGAAAAAGGAAGGAAGAAGAAGCAATTCCCTGTGCTTGA	446
20	2451	AGAGATGATAATTCACGAGTGCCCTTTTCTGACCCTTTCTTCTAATCTTA	2500
	445	AGAGATGATAATTCACGAGTGCCCTTTCTGACCCTTTCTTCTAATCTTA	396
25	2501	GGGCTCTTACTTCCCTCAGAATTTGCTATAATAAAGTAGCTACTTCATTC	2550
	395	GGGCTCTTACTTCCCTCAGAATTTGCTATAAAAGTAGCTACTTCATTC	346
30	2551	CCAGAAGAGTTTCAAAAACCTTGCAAATCTCAAATACTTGACAATCTC	2600
30	345	CCAGAAGAGATGTTCAAAAACCTTGCAAATCTCAAATACTTGACAATCTC	296
	2601	TCGGTGCAATAATCTCAAAGAGCTGCCTACCAGCTTGGCTAGTCTGAATG	2650
35	295	TCGGTGCAATAATCTCAAAGAGCTGCCTACCAGCCTGGCTAGTCTGAATG	246
	2651	CTTTGAAAAGTCTAAAAATTCAATTGTGTTGCGCACTAGAGAGTCTCCCT	2700
40	245	CTTTGAAAAGTCTAGCACTAGAGAGTCTCCCT	214
	2701	GAGGAAGGCTTGGAAGGTTTATCTTCACTCACAGAGTTATTTGTTGAACA	2750
	213	GAGGAAGGGCTGGAAGGTTATCTTCACTCACAGAGTTATTTGTTGAACA	164
45	2751	CTGTAACATGCTAAAATGTTTACCAGGGGGTTGCAGCACCCTAACAACCC	2800
	163	CTGTAACATGUTGAAATGTTTACCAGAGGGATTGCAGCACCTAACAACCC	114
50	2801	TCACAAGTTTAAAAATTCGGGGATGTCCACAACTGATCAAGCGGTGTGAG	2850
	113	TCACAAGTTTAAAAATTCGGGGATGTCCACAACTGATCAAGCGGTGTGAG	64
	2851	AAGGGAATAGGAAGACTGGCACAAAATTTCTCACATTCCTAATGTGAA	2900
55	63	AAGGGAATAGGAGAAGACTGGCACAAAATTTCTCACATTCCTAATGTGAA	14
	2901	TATATATATTAA 2913	
60	. 13	TATATATATTAA 1	

- 47 -

## Appendix III

EDGLLG, STEPEPO

#### P03170US/WARF-0204

#### SEQ ID NO:5: Gene 2 protein sequence (from the resistant homolog).

GCTTTGAGTTCTTTTCTTTATGGATCCCG

- 20 MAEAFIQVLLDNLTSFLKGELVLLFGFQDEFQRLSSMFSTIQAVLEDAQEKQLNNKPLENWLQKLNAATY
  EVDDILDEYKTKATRFSQSEYGRYHPKVIPFRHKVGKRMDQVMKKLKAIAEERKNFHLHEKIVERQAVRR
  ETGSVLTEPQVYGRDKEKDEIVKILINNVSDAQHLSVLPILGMGGLGKTTLAQMVFNDQRVTEHFHSKIW
  ICVSEDFDEKKLIKAIVESIEGRPLLGEMDLAPLQKKLQELLNGKRYLLVLDDVWNEDQQKWANLRAVLK
  VGASGASVLTTTRLEKVGSIMGTLQPYELSNLSQEDCWLLFMQRAFGHQEEINPNLVAIGKEIVKKSGGV
  25 PLAAKTLGGILCFKREERAWEHVRDSPIWNLPQDESSILPALRLSYHQLPLDLKQCFAYCAVFPKDAKMK
  KEKLISLWMAHGFLLSKGNMELEDVGDEVWKELYLRSFFQEIEVKDGKTYFKMHDLIHDLATSLFSANTS
  SSNIREINKHSYTHMMSIGFAEVVFFYTLPPLEKFISLRVLNLGDSTFNKLPSSIGDLVHLRYLNLYGSG
  MRSLPKQLCKLQNLQTLDLQYCTKLCCLPKETSKLGSLRNLLLDGSQSLTCMPPRIGSLTCLKTLGQFVV
  GRKKGYQLGELGNLNLYGSIKISHLERVKNOMDAKEANLSAKGNLHSLSMSWNNFGPHIYESEEVKVLEA
  30 LKPHSNLTSLKIYGFRGIHLPEWMNHSVLKNIVSILISNFRNCSCLPPFGDLPCLESLELHWGSADVEYV
  EEVDIDVHSGFPTRIRFFSLRKLDIWDFGSLKGLLKKEGEEQFPVLEEMIIHECPFLTLSSNLRALTSLR
  ICYNKVATSFPEEMFKNLANLKYLTISRCNNLKELPTSLASLNALKSLKIQLCCALESLPEEGLEGLSSL
  TELFVEHCNMLKCLPEGLQHLTTLTSLKIRGCPQLIKRCEKGIGEDWHKISHIPNVNIYI
- 35 SEQ ID NO:6: Nucleic acid sequence of disease resistant gene, gene 3 (from the resistant homolog)
- ATGGCTGAAGCTTTCCTTCAAGTTCTGCTAGATAATCTCACTTTTTTCATCCAAGGGGAACTTGGATTGG TTTTTGGTTTCGAGAAGGAGTTTAAAAAACTTTCAAGTATGTTTTCAATGATCCAAGCTGTGCTAGAAGA  ${\tt TGCTCAAGAGCAACTGAAGTACAAGGCAATAAAGAACTGGTTACAGAAACTCAATGTTGCTGCATAT}$ GAAGTTGATGACATCTTGGATGACTGTAAAACTGAGGCAGCAAGATTCAAGCAGGCTGTATTGGGGCGTT ATCATCCACGGACCATCACTTTCTGTTACAAGGTGGGAAAAGAATGAAGAAATGATGGAAAAACTAGA TGCAATTGCAGAGGAACGGAGGAATTTTCATTTAGATGAAAGGATTATAGAGAGACAAGCTGCTAGACGG CAAACAGGTTTTGTTTTAACTGAGCCAAAAGTTTATGGAAGGGAAAAAGAGGAGGATGAGATAGTGAAAA TCTTGATAAACAATGTTAGTTATTCCGAAGAAGTTCCAGTACTCCCAATACTTGGTATGGGGGGACTAGG AAAGACGACTCTAGCCCAAATGGTCTTCAATGATCAAAGAATTACTGAGCATTTCAATCTAAAGATATGG GTTTGTGTCTCAGATGATTTTGATGAGAAGAGGTTGATTAAGGCAATTGTAGAATCTATTGAAGGAAAGT CACTGGGTGACATGGACTTGGCTCCCCTCCAGAAAAAGCTTCAGGAGTTGTTGAATGGAAAAAGATACTT **TCTTGTTTTGGATGTTTGGAATGAAGATCAAGAAAAGTGGGATAATCTTAGAGCAGTATTGAAGATT** GGAGCTAGTGGTGCTTCAATTCTAATTACTACTCGTCTTGAAAAAATTGGATCAATTATGGGAACTTTGC CCAAACCGAAACAAGTCCTAAACTTATGGAAATCGGAAAGGAGATTGTGAAGAAATGTGGGGGTGTGCCT CTAGCAGCCAAAACTCTTGGAGGCCTTTTACGCTTCAAGAGGGAAGAAAGTGAATGGGAACATGTGAGAG TCTTCCACTTGATTTGAGACAATGTTTTGCATATTGCGCAGTATTCCCAAAGGACACCAAAATAGAAAAG GAATATCTCATCGCTCTCTGGATGGCACACAGTTTTCTTTTATCAAAAGGAAACATGGAGCTAGAGGATG